* If you want to update the article please login/register
In this phase 2 clinical trial, thirteen consecutive adults with lymphoma or myeloma will be included. Patients will be divided 1:1 in two groups: one subcutaneous 6 mg dose of generic pegfilgrastim or one 6 mg dose of brand-name pegfilgrastim will be administered in two groups on day +1 after the autotransplant. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05338047
"A prospective, randomized, open-label, multicenter, parallel experiment, observational study to determine the safety and efficacy of 200 kidney transplant recipients comparing brand tacrolimus to generic tacrolimus over a one-year follow-up period. " In the first 14 days after transplantation, the study population includes recipients of kidney allografts. If the subject needs more study drug preparations before his or her next study visit, the patient will come into the clinic to get a fresh supply. Review and sign this consent form This is the beginning of your medical history Review of your latest medications Review of your medical history Summary of your current medications Including vital signs, height, and weight Evaluation of clinical labs If you are in Part 1 of the survey, you will receive your study drug. If you are a woman of child bearing potential, a pregnancy test will be completed prior to the study's commencement. During the 1-year study period and six weeks after the last dose of study drugs was administered, you must use a medically acceptable method of birth control. After the study doctor reviews your medical history and test findings, he or she may inform you that you do not qualify to enroll in the study.
Source link: https://clinicaltrials.gov/ct2/show/NCT02866682
"The main purpose of regimen switching is to maintain viral suppression without jeopardizing future therapy options. To simplify the regimen, minimize the drug use and dosing frequency, reduce the risk of acute and long-term toxicities, and eliminate the dietary requirements, it is important to consider regimen switching in the viral suppressed population. All participants will be switched from their pre-study ART regimen to a single tablet regimen of TAF/FTC/DTG 25/200/50 mg/day once daily.
Source link: https://clinicaltrials.gov/ct2/show/NCT03727152
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions